![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAP7D2 |
Gene summary for MAP7D2 |
![]() |
Gene information | Species | Human | Gene symbol | MAP7D2 | Gene ID | 256714 |
Gene name | MAP7 domain containing 2 | |
Gene Alias | MAP7D2 | |
Cytomap | Xp22.12 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q96T17 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
256714 | MAP7D2 | C43 | Human | Oral cavity | OSCC | 2.05e-28 | 6.15e-01 | 0.1704 |
256714 | MAP7D2 | C46 | Human | Oral cavity | OSCC | 3.19e-03 | 8.29e-02 | 0.1673 |
256714 | MAP7D2 | LN22 | Human | Oral cavity | OSCC | 4.06e-06 | 7.92e-01 | 0.1733 |
256714 | MAP7D2 | LN38 | Human | Oral cavity | OSCC | 8.69e-03 | 4.00e-01 | 0.168 |
256714 | MAP7D2 | LN46 | Human | Oral cavity | OSCC | 1.74e-05 | 2.94e-01 | 0.1666 |
256714 | MAP7D2 | SYSMH1 | Human | Oral cavity | OSCC | 5.62e-06 | 1.10e-01 | 0.1127 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP7D2 | SNV | Missense_Mutation | novel | c.1582N>A | p.Glu528Lys | p.E528K | Q96T17 | protein_coding | deleterious(0) | benign(0.359) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP7D2 | SNV | Missense_Mutation | rs774230355 | c.394N>T | p.Arg132Cys | p.R132C | Q96T17 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP7D2 | SNV | Missense_Mutation | rs764743272 | c.361N>T | p.Arg121Trp | p.R121W | Q96T17 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP7D2 | SNV | Missense_Mutation | c.1518G>T | p.Lys506Asn | p.K506N | Q96T17 | protein_coding | tolerated(0.1) | benign(0.274) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
MAP7D2 | SNV | Missense_Mutation | c.424G>C | p.Glu142Gln | p.E142Q | Q96T17 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-JW-A5VJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
MAP7D2 | SNV | Missense_Mutation | c.165N>C | p.Gln55His | p.Q55H | Q96T17 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
MAP7D2 | SNV | Missense_Mutation | c.1151N>A | p.Arg384Lys | p.R384K | Q96T17 | protein_coding | tolerated(0.61) | benign(0.003) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
MAP7D2 | SNV | Missense_Mutation | rs774743082 | c.1124N>T | p.Ala375Val | p.A375V | Q96T17 | protein_coding | deleterious(0) | possibly_damaging(0.817) | TCGA-VS-A8QH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | gemcitabine | PD |
MAP7D2 | SNV | Missense_Mutation | rs199956389 | c.1325N>T | p.Ala442Val | p.A442V | Q96T17 | protein_coding | deleterious(0.03) | benign(0.285) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP7D2 | SNV | Missense_Mutation | c.1756G>T | p.Asp586Tyr | p.D586Y | Q96T17 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |